b r i e f c o m m u n i c a t i o n s
To understand the genetic mechanisms driving variant and IGHV4-34-expressing hairy-cell leukemias, we performed whole-exome sequencing of leukemia samples from ten affected individuals, including six with matched normal samples. We identified activating mutations in the MAP2K1 gene (encoding MEK1) in 5 of these 10 samples and in 10 of 21 samples in a validation set (overall frequency of 15/31), suggesting potential new strategies for treating individuals with these diseases.
Hairy-cell leukemia-variant (HCLv) is a chronic mature B cell neoplasm with little available data regarding the genetic mechanisms driving pathogenesis. HCLv shares pathological features with classic hairy-cell leukemia (HCLc), but the two malignancies have distinct morphologies, immunophenotypes, molecular signatures and clinical courses. Accordingly, they are classified separately by the latest World Health Organization guidelines. Whereas purine analog therapy (e.g., cladribine or pentostatin) leads to median survival of over 20 years and durable complete remission in the vast majority of individuals with HCLc, it is largely ineffective in HCLv, where only 50% of individuals exhibit even a partial response.
It has recently been shown that 40% of HCLv samples and 10% of HCLc samples express the IGHV4-34 immunoglobulin variable heavy chain rearrangement (IGHV4-34 positive). Independent of diagnosis with variant or classic HCL, IGHV4-34 expression is associated with higher disease burden at diagnosis, poor response to single-agent cladribine and shorter overall survival 1 .
HCLc was recently shown to be driven almost universally by the oncogenic activating p.Val600Glu alteration encoded in the serine/ threonine kinase BRAF 2 . This finding has been validated multiple times, and targeted therapy for BRAF Val600Glu has shown clinical benefit in refractory HCLc 3 . However, multiple reports have been unable to identify instances of BRAF mutation at codon 600 in either HCLv or IGHV4-34-positive HCLc 2,4-6 .
We performed whole-exome sequencing on ten HCL samples that were either variant (n = 5), IGHV4-34-positive (n = 3) or both (n = 2) (Supplementary Table 1 ). Differentiating HCLv from splenic marginal zone lymphoma (SMZL) and similar entities can be difficult or sometimes even impossible, particularly without splenic pathology. However, the presence of CD103 and absence of CD25 on leukemia cells in nearly all of the HCLv cases supports this diagnosis, and diagnosis of the two CD103-negative cases was supported by the results of splenic tissue analysis. Each tumor sample had a corresponding post-treatment blood sample for use as a matched normal control. Sequencing was performed on the Illumina HiSeq platform with paired-end 101-bp reads to an average depth of 46× (Supplementary Table 2 ). Analysis of sample purity showed that, whereas all tumor samples had minimal contamination from normal tissue, four of the post-treatment blood samples still had high tumor content and were insufficient for identifying somatic variants ( Supplementary Fig. 1 ). These blood samples were therefore discarded, leaving six matched and four unmatched tumor samples (Online Methods). In filtering the variant calls to identify candidate driver genes (Online Methods) we identified five recurrent mutation targets: MAP2K1, U2AF1, ARID1A, TP53 and TTN ( Table 1) .
The most frequently mutated gene was MAP2K1, with mutations occurring in five of ten separate samples. We validated this finding in a set of 21 additional samples (Supplementary Table 1 ). Sanger sequencing of the affected exons (exons 2 and 3) identified ten additional mutation-positive samples for an overall frequency of 48% (95% confidence interval (CI) of 30-67%) (Supplementary Table 3 ). MAP2K1 mutations occurred in all three subtypes of HCL examined (6 of 15 IGHV4-34-negative HCLv, 4 of 9 IGHV4-34-positive HCLv and 5 of 7 IGHV4-34-positive HCLc overall), with no significant differences in frequency between subtypes (P > 0.1 for all pairwise comparisons by Fisher's exact test). MAP2K1 encodes the dual-specificity kinase MEK1, which is a direct effector of BRAF and is directly upstream of the extracellular signal-regulated kinases ERK1 and ERK2 in the mitogen-activated protein kinase (MAPK) pathway. The BRAF mutation encoding p.Val600Glu was identified in 1 of the 10 tumors in the initial whole-exome sequencing discovery set as well as in 2 of the 21 samples from the validation set by TaqMan PCR and was mutually exclusive with MAP2K1 mutations (Supplementary Table 3 ). MAP2K1 mutations have been identified infrequently in the developmental disorder cardiofaciocutaneous (CFC) syndrome and in several cancers (including melanoma, ovarian carcinoma, colorectal carcinoma and non-small-cell lung cancer), and they have also recently emerged as a mode of resistance to targeted therapy of BRAF Val600Glu 7 . With the exception of one instance of SMZL 8 , MAP2K1 mutations have not been reported in any hematologic malignancy and have never been reported to occur in any cancer with an incidence approaching the frequency reported here for HCL. The mutations we identified in MAP2K1 mapped to the regions encoding the negative regulatory region, the catalytic core (but not the active site) and the intervening linker 7 (Fig. 1) . All but one of the mutations were substitutions, most of which have been identified before, either in samples from other types of cancer or by in vitro screens, and have been shown to strongly increase basal enzymatic activity and cell proliferation [9] [10] [11] [12] . The only non-substitution mutation was a 48-bp in-frame deletion (amino acids 42 through 57) that almost entirely removed the autoinhibitory helix A 13 . A highly similar deletion (involving residues 44 through 51) has been shown to increase basal activity of the enzyme by 60-fold 14 . These findings are particularly notable because MEK inhibitors have undergone intense development as a tool to suppress mitogenic signaling and complement the clinical benefit derived from inhibitors of mutant BRAF 15 . Current MEK inhibitors function by an allosteric mechanism that is dependent on the same N-terminal autoinhibitory domain where the alterations cluster. The most common mutation in our samples encoding p.Cys121Ser as well as those encoding p.Ile103Asn and p.Gln56Pro have previously been shown to confer resistance to current MEK inhibitors 9, 10 , whereas MEK1 harboring the p.Lys57Asn alteration remains sensitive 11 . Thus, although the current repertoire of MEK inhibitors is not expected to be clinically beneficial for all individuals with activating MAP2K1 mutations, MEK1 and its effector ERK remain very attractive targets for therapy in HCL. The uniquely high incidence of MAP2K1 mutations may also be useful in the diagnosis of these leukemias.
To validate the association of MAP2K1 mutations with these forms of HCL, we also investigated 20 cases of IGHV4-34-negative HCLc (Supplementary Table 1) . Seventeen of these cases were positive for BRAF mutations encoding p.Val600Glu, and 1 case had a MAP2K1 mutation encoding p.Phe53Leu (Supplementary Table 3) , supporting previous findings that BRAF p.Val600Glu is largely specific to IGHV4-34-negative HCLc.
The robust segregation of mutations in BRAF and MAP2K1 with different forms of HCL demonstrates that the mutations are not redundant in this context, possibly owing to quantitatively different effects on pathway activation, qualitatively different effects on feedback pathways or other mechanisms.
Our whole-exome sequencing analysis identified four additional candidate driver genes, each mutated in two of ten cases: TP53, U2AF1, ARID1A and TTN. We did not pursue TTN because it encodes the longest protein in the genome with a well-described musclespecific function, and the mutations are therefore likely to be passengers. TP53 is the most commonly mutated gene across all cancers, and somatic mutation and loss of heterozygosity at this locus have previously been associated specifically with HCLv 16 . U2AF1 encodes a component of the splicing machinery that recognizes and binds to the 3′ splice site. The hotspot p.Ser34Phe alteration was found in two of the ten samples from the discovery set and has been observed before in several other hematopoietic malignancies 17 and in a small fraction of lung adenocarcinomas 18 . Among hematopoietic malignancies, U2AF1 mutations have previously been restricted to myeloid disorders; however, the splicing machinery component SF3B1 is mutated in roughly 10% of chronic lymphocytic leukemias, another mature B cell malignancy. We performed Sanger sequencing of this U2AF1 hotspot in our validation set and identified one additional mutationpositive case (Supplementary Table 3) . It should be noted that, in the two initial p.Ser34Phe-positive samples, the variant allele frequency was low (17% and 22%), possibly owing to the mutation being subclonal, and some U2AF1 mutations could thus be below the level of b r i e f c o m m u n i c a t i o n s npg detection for Sanger sequencing. Two of the ten initial samples contained truncating mutations in the tumor suppressor ARID1A, which encodes a core component of the ATP-dependent SWI/SNF chromatinremodeling complex. Loss-of-function mutations in ARID1A have been identified in many different cancers, including in several B cell malignancies 19 . In conclusion, we find a remarkably high frequency of MAP2K1 mutations in variant and IGHV4-34-expressing HCLs. The development of inhibitors to these altered forms of MEK1 or to its presumed target ERK could transform the treatment of individuals with these leukemias.
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